Cargando…

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma

Mutations in Human Epidermal Growth Factor Receptors (HER) are associated with poor prognosis of several types of solid tumors. Although HER-mutation detection methods are currently available, such as Next-Generation Sequencing (NGS), alternative pyrosequencing allow the rapid characterization of sp...

Descripción completa

Detalles Bibliográficos
Autores principales:	González-Alonso, Paula, Chamizo, Cristina, Moreno, Víctor, Madoz-Gúrpide, Juan, Carvajal, Nerea, Daoud, Lina, Zazo, Sandra, Martín-Aparicio, Ester, Cristóbal, Ion, Rincón, Raúl, García-Foncillas, Jesús, Rojo, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581306/ https://www.ncbi.nlm.nih.gov/pubmed/26287187 http://dx.doi.org/10.3390/ijms160819447

Ejemplares similares

Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer
por: González-Alonso, Paula, et al.
Publicado: (2020)

Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2021)

Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer
por: Chamizo, Cristina, et al.
Publicado: (2015)

The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models
por: Sanz-Álvarez, Marta, et al.
Publicado: (2021)

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
por: Madoz-Gúrpide, Juan, et al.
Publicado: (2015)

Potential therapeutic value of miR‐425‐5p in metastatic colorectal cancer
por: Cristóbal, Ion, et al.
Publicado: (2016)

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
por: Cabello, Paula, et al.
Publicado: (2023)

HER2 somatic mutations are associated with poor survival in HER2‐negative breast cancers
por: Wang, Tonghui, et al.
Publicado: (2017)

Comment on ‘MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells’
por: Cristóbal, Ion, et al.
Publicado: (2017)

Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells
por: Santos, Andrea, et al.
Publicado: (2023)

Activating HER3 mutations in breast cancer
por: Mishra, Rosalin, et al.
Publicado: (2018)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
por: Gaibar, Maria, et al.
Publicado: (2020)

Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
por: Harada, Yohei, et al.
Publicado: (2023)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer
por: Cristóbal, I, et al.
Publicado: (2014)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
por: Rincón, Raúl, et al.
Publicado: (2015)

Low MicroRNA-19b Expression Shows a Promising Clinical Impact in Locally Advanced Rectal Cancer
por: Rubio, Jaime, et al.
Publicado: (2021)

Validation of microRNA-199b as A Promising Predictor of Outcome and Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients
por: Cristóbal, Ion, et al.
Publicado: (2021)

MicroRNA-19b Plays a Key Role in 5-Fluorouracil Resistance and Predicts Tumor Progression in Locally Advanced Rectal Cancer Patients
por: Santos, Andrea, et al.
Publicado: (2022)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
por: Mu, Yuxin, et al.
Publicado: (2023)

Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
por: Koyama, Kumiko, et al.
Publicado: (2022)

Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer
por: Cristóbal, Ion, et al.
Publicado: (2015)

SDPS-10 DISPARITIES IN THE RISK OF CNS METASTASIS AND CLINICAL OUTCOMES IN PATIENTS WITH HER2- MUTATION POSITIVE (HER2+) NON-BREAST VERSUS HER2+ BREAST CANCERS
por: Elghawy, Omar, et al.
Publicado: (2023)

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells
por: Serwotka-Suszczak, Anna M., et al.
Publicado: (2017)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer
por: Cristóbal, Ion, et al.
Publicado: (2016)

HER2 Amplification in p53-Mutated Endometrial Carcinomas
por: Balestra, Ambre, et al.
Publicado: (2023)

HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2‐negative patients
por: Si, Pilei, et al.
Publicado: (2017)

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
por: Tian, Hao, et al.
Publicado: (2023)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells
por: Damiani, Isabella, et al.
Publicado: (2021)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

“Everything for Her!”
por: Andrijević Matovac, Vesna
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_2nsdmlqspbdc2v68vu1knecbl4